Evidence map›Paper›PMID 34447289›Full record

ArticlePathology oncology research : POR2021

The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.

Hui Yang, Kunlun Wang, Shenglei Li, Yan Li, Ling Yuan

Abstract read
In one paragraph

Article in Pathology oncology research : POR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hui YangDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Kunlun WangDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Shenglei LiDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Yan LiDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Ling YuanDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedBiomarkers, TumorCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantErbB ReceptorsFemaleHumansLung NeoplasmsMaleMiddle AgedMutationNeoplasm StagingPneumonectomyPrognosisRadiotherapy, AdjuvantBiomarkers, TumorEGFR protein, humanErbB ReceptorsEGFRNSCLCpostoperative radiotherapyprognostic factorsstage IIIA/N2

Identifiers

PMID34447289
PMCPMC8382988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.